Stay updated on Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-03T23:42:45.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    An NIH-wide notice about the terminology transition appears above the 403 error page, and the site revision label changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T23:41:07.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The site's footer revision label changed from v3.7.0 to v3.7.1, while the page continues to show a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-13T23:40:24.000Z thumbnail image
  5. Check
    47 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden error, replacing the usual study details with an error screen. A Home button is provided to navigate away from the blocked page.
    Difference
    21%
    Check dated 2026-09-23T00:51:41.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    Revision number updated from v3.6.6 to v3.7.0, indicating a new page version and routine maintenance. This change does not modify study content, eligibility criteria, or any user-facing information on the page.
    Difference
    0.0%
    Check dated 2026-09-16T00:08:20.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    The page's revision label was updated from v3.6.5 to v3.6.6, indicating a minor update to the Study Details page. This reflects a page metadata revision rather than modifications to the study data or eligibility criteria.
    Difference
    0.0%
    Check dated 2026-09-01T19:31:59.000Z thumbnail image

Stay in the know with updates to Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page.